Optimal treatment for relapsing ovarian cancer

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Ledermann, J A ^a   Kristeleit, R S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Ovarian cancer; Platinum refractory; Platinum resistant; Platinum sensitive; Relapse; Targeted therapy

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BGC 945; CARBOPLATIN; CEDIRANIB; DASATINIB; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; ETOPOSIDE; EVEROLIMUS; FARLETUZUMAB; GEMCITABINE; LEUPRORELIN; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OSI 906; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; RAPAMYCIN; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZIBOTENTAN;

CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; MORBIDITY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC AGENTS; CALIBRATION; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RECURRENCE;

EID: 78649348155     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq377     Document Type: Conference Paper

References (41)

1. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006; 98: 1655-1663.
2. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99: 393-399.
3. International Collaboration for Ovarian Neoplasia Group. Paclitaxel plus platinum- based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
4. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
5. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J clin Oncol 2010; 28: 3107-3114.
6. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
7. Poveda A, Tjulandin S, Kong B et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: results from a PPS cohort of a phase III study. J Clin Oncol 2010; 28: 7s (Abstr 5012).
8. Rustin G, van der Burg M et al. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009; 27 (Suppl): 18s (Abstr 1).
9. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-1710.
10. Cree IA, Kurbacher CM, Lamont A et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007; 18: 1093-1101.
11. Cadron I, Leunen K, Amant F et al. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol 2007; 106: 354-361.
12. Sharma R, Graham J, Mitchell H et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009; 100: 707-712.
13. Fung-Kee-Fung M, Oliver T, Elitx L et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195-208.
14. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
15. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436-440.
16. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000; 7: 85-93.
17. du Bois A, Meier W, Luck HJ et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002; 13: 251-257.
18. Kristensen G, Kaern J, Baekelandt M et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study. J Clin Oncol 2008: 26 Abstr 5508.
19. Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009; 9: 1727-1735.
20. Vergote I, Calvert H, Kania M et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009; 45: 1415-1423.
21. Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs 2006; 15: 691-702.
22. De Geest K, Blessing JA, Morris RT et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2010; 28: 149-153.
23. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1-7.
24. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165-5171.
25. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
26. Steelman LS, Stadelman KM, Chappell WH et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008; 12: 1139-1165.
27. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9: 167-181.
28. Eckstein N, Servan K, Hildebrandt B et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; 69: 2996-3003.
29. Huang GS, Brouwer-Visser J, Ramirez MJ et al. Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010; 16: 2999-3010.
30. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 2005; 4: 217-224.
31. Ledermann J, Rustin G, Hackshaw A et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009; 27: 15s (Abstr 5501).
32. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010; 10: 431-437.
33. Gibbs DD, Theti DS, Wood N et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005; 65: 11721-11728.
34. Kalli KR, Oberg AL, Keeney GL et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; 108: 619-626.
35. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115.
36. Audeh M, Penson R, Friedlander M et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27: 15s (Abstr 5500).
37. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
38. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
39. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 2008; 26: 3259-3267.
40. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
41. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.